Immunotherapy boosts standard chemoradiation in HPV+ throat cancer trial
NCT ID NCT03829722
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether adding the immunotherapy drug nivolumab to standard radiation and chemotherapy can help prevent cancer from returning in people with high-risk HPV-related throat cancer. The trial enrolled 26 participants with advanced-stage disease. Researchers measured how long participants lived without their cancer growing or spreading after treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OROPHARYNX SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Michigan Rogel Cancer Center
Ann Arbor, Michigan, 48109, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New pastille could change head and neck cancer treatment
- New study aims to cut side effects in throat cancer treatment
- Simple breathing trick may help cancer survivors swallow safely
- Blood test may predict throat cancer comeback
- New drug duo offers hope for hard-to-treat head and neck cancer
- Collagen patch after oral cancer surgery: does it help you swallow and speak?